Karyopharm Therapeutics Inc at JPMorgan Healthcare Conference (Virtual) Transcript
All right. Good afternoon, and thanks again for joining us for the Annual JPMorgan Healthcare Conference. I'm Eric Joseph, senior biotech analyst at the firm. And our next presenting company is Karyopharm Therapeutics, and it is my pleasure to welcome and introduce CEO, Michael Kauffman, to tell us a little bit about the company.
Before I hand it over to -- hand it over, let me just remind folks that there is a Q&A session after the presentation. Please do feel free to submit a question that I'll ask on your behalf by clicking the ask a question icon. And with that, Michael, take it away.
Thank you very much, Eric. It's great to be here, and thank you all for joining us today to discuss Karyopharm's recent progress in our pursuit of improving the lives of patients with cancer.
Before I begin, let me remind you of the standard remarks I'll make today constitute forward
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |